Overview

Motor neurone disease (MND) is a group of progressive disorders that damage the nerve cells responsible for voluntary muscle control. The condition is often referred to as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS) in its common form. Clinically it is recognised as a serious neurological disease that gradually reduces a person's ability to move, speak, swallow and breathe while sparing most involuntary functions.

Key features and progression

MND primarily affects motor neurons in the brain and spinal cord that signal muscles to contract. Damage to these cells leads to muscle weakness, wasting (atrophy), stiffness and cramps. Over time this causes increasing disability, and ultimately death in many cases, usually from complications such as respiratory failure. The disease can affect both upper motor neurons (in the brain) and lower motor neurons (in the brainstem and spinal cord), producing a mix of spasticity and flaccid weakness.

Causes and biological background

MND has diverse causes. Most cases are sporadic, but about 5–10% are inherited. Genetic research has identified several genes associated with familial and some sporadic forms, including SOD1 and C9orf72, among others. Pathologically, there is progressive loss of motor neurons within the central nervous system, leading to failure of neural pathways that start and control voluntary movement.

Diagnosis and clinical evaluation

Diagnosis is clinical and based on the pattern of symptoms and signs, supported by tests that exclude other conditions. Electromyography (EMG) and nerve conduction studies help document motor neuron dysfunction. Magnetic resonance imaging and blood tests rule out mimics. Because MND can appear in different ways, specialist assessment and repeated examinations are often required to confirm the diagnosis.

Management and supportive care

There is no cure for MND, but several strategies can improve quality of life and extend survival. Drug therapy may modestly slow progression for some patients; multidisciplinary care is important. Typical supportive measures include:

  • medication and clinical trials aimed at slowing neuron loss;
  • physiotherapy and occupational therapy to preserve mobility and independence;
  • speech and swallowing support, including communication aids;
  • nutrition management and gastrostomy feeding when needed;
  • respiratory support such as non-invasive ventilation.

Prognosis, cognition and notable distinctions

While MND primarily targets movement, many people retain cognitive skills for a long time; functions such as intelligence, memory and personality may be preserved. However, a subset of patients develop cognitive or behavioural changes consistent with frontotemporal dementia, and this overlap is an active area of research. The course varies widely: some progress quickly over months to a few years, while others live many years with gradual decline.

Historical and social context

The name "Lou Gehrig's disease" reflects a well-known historical association that helped raise public awareness. Interest in MND has driven research into genetics, neurodegeneration and supportive care models. Today, emphasis on multidisciplinary clinics, assistive technologies and palliative planning aims to maximise comfort and autonomy for those affected.

For additional background, clinical guidance and research summaries consult specialist sources and clinical centres that focus on motor neurone disease and amyotrophic lateral sclerosis for up-to-date information and local services.